129 related articles for article (PubMed ID: 37524214)
1. A computational-based approach to fabricate Ceritinib co-amorphous system using a novel co-former Rutin for bioavailability enhancement.
Yarlagadda DL; Anand VSK; Nair AR; Dengale SJ; Pandiyan S; Mehta CH; Manandhar S; Nayak UY; Bhat K
Eur J Pharm Biopharm; 2023 Sep; 190():220-230. PubMed ID: 37524214
[TBL] [Abstract][Full Text] [Related]
2. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.
Dengale SJ; Ranjan OP; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Sci; 2014 Oct; 62():57-64. PubMed ID: 24878386
[TBL] [Abstract][Full Text] [Related]
3. Co-amorphous systems using epigallocatechin-3-gallate as a co-former: Stability, in vitro dissolution, in vivo bioavailability and underlying molecular mechanisms.
Chen J; Li H; Li X; Yuan D; Cheng H; Ke Y; Cheng J; Wang Z; Chen J; Li J
Eur J Pharm Biopharm; 2022 Sep; 178():82-93. PubMed ID: 35932965
[TBL] [Abstract][Full Text] [Related]
4. Tranilast-matrine co-amorphous system: Strong intermolecular interactions, improved solubility, and physiochemical stability.
Hu D; Chen X; Li D; Zhang H; Duan Y; Huang Y
Int J Pharm; 2023 Mar; 635():122707. PubMed ID: 36764418
[TBL] [Abstract][Full Text] [Related]
5. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
6. Fabrication, solid state characterization and bioavailability assessment of stable binary amorphous phases of Ritonavir with Quercetin.
Dengale SJ; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Biopharm; 2015 Jan; 89():329-38. PubMed ID: 25542681
[TBL] [Abstract][Full Text] [Related]
7. Co-amorphous formulation of dipyridamole with p-hydroxybenzoic acid: Underlying molecular mechanisms, physical stability, dissolution behavior and pharmacokinetic study.
Guo W; Dong X; Li Y; Li C; Tian Y; Gao H; Li T; Zhu H; Wang J; Yang C
Eur J Pharm Biopharm; 2023 Mar; 184():139-149. PubMed ID: 36709922
[TBL] [Abstract][Full Text] [Related]
8. Preparation and tableting of long-term stable amorphous rutin using porous silica.
Wei Q; Keck CM; Müller RH
Eur J Pharm Biopharm; 2017 Apr; 113():97-107. PubMed ID: 27847275
[TBL] [Abstract][Full Text] [Related]
9. Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability.
Shuai S; Yue S; Huang Q; Wang W; Yang J; Lan K; Ye L
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):413-22. PubMed ID: 25669445
[TBL] [Abstract][Full Text] [Related]
10. Amorphous System of Hesperetin and Piperine-Improvement of Apparent Solubility, Permeability, and Biological Activities.
Wdowiak K; Miklaszewski A; Pietrzak R; Cielecka-Piontek J
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902286
[TBL] [Abstract][Full Text] [Related]
11. [The development of co-amorphous drug systems].
Yao J; Shi NQ; Wang XL
Yao Xue Xue Bao; 2013 May; 48(5):648-54. PubMed ID: 23888685
[TBL] [Abstract][Full Text] [Related]
12. Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study.
Chavan RB; Lodagekar A; Yadav B; Shastri NR
Drug Deliv Transl Res; 2020 Aug; 10(4):903-918. PubMed ID: 32378174
[TBL] [Abstract][Full Text] [Related]
13. Structural, thermal, vibrational, solubility and DFT studies of a tolbutamide co-amorphous drug delivery system for treatment of diabetes.
R Sá M; Sarraguça JMG; de Sousa FF; Sarraguça MSC; Lopes JA; Lima ADDSG; Lage MR; Ribeiro PRS
Int J Pharm; 2022 Mar; 615():121500. PubMed ID: 35077862
[TBL] [Abstract][Full Text] [Related]
14. Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability.
Liu P; Zhou JY; Chang JH; Liu XG; Xue HF; Wang RX; Li ZS; Li CS; Wang J; Liu CZ
Drug Des Devel Ther; 2020; 14():2959-2975. PubMed ID: 32801637
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of Complexation into a Coamorphous System Dramatically Enhances Dissolution and Eliminates Gelation of Amorphous Lurasidone Hydrochloride.
Heng W; Su M; Cheng H; Shen P; Liang S; Zhang L; Wei Y; Gao Y; Zhang J; Qian S
Mol Pharm; 2020 Jan; 17(1):84-97. PubMed ID: 31794225
[TBL] [Abstract][Full Text] [Related]
16. Characterization and therapeutic efficacy evaluation of glimepiride and L-arginine co-amorphous formulation prepared by supercritical antisolvent process: Influence of molar ratio and preparation methods.
Park H; Jin Seo H; Hong SH; Ha ES; Lee S; Kim JS; Baek IH; Kim MS; Hwang SJ
Int J Pharm; 2020 May; 581():119232. PubMed ID: 32240805
[TBL] [Abstract][Full Text] [Related]
17. Improved Oral Absorption of Poorly Soluble Curcumin via the Concomitant Use of Borneol.
Gao Y; Chen G; Luan X; Zou M; Piao H; Cheng G
AAPS PharmSciTech; 2019 Mar; 20(4):150. PubMed ID: 30903519
[TBL] [Abstract][Full Text] [Related]
18. Sinapic Acid Co-Amorphous Systems with Amino Acids for Improved Solubility and Antioxidant Activity.
Garbiec E; Rosiak N; Tykarska E; Zalewski P; Cielecka-Piontek J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982605
[TBL] [Abstract][Full Text] [Related]
19. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior.
Fael H; Demirel AL
Int J Pharm; 2020 May; 581():119284. PubMed ID: 32243965
[TBL] [Abstract][Full Text] [Related]
20. Characterization of co-amorphous carvedilol-maleic acid system prepared by solvent evaporation.
Furuishi T; Sato-Hata N; Fukuzawa K; Yonemochi E
Pharm Dev Technol; 2023; 28(3-4):309-317. PubMed ID: 36946594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
